These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30769277)

  • 1. Pharmacological advances in pemphigoid.
    Maglie R; Hertl M
    Curr Opin Pharmacol; 2019 Jun; 46():34-43. PubMed ID: 30769277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
    James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
    Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophils as putative therapeutic targets in bullous pemphigoid.
    Simon D; Borradori L; Simon HU
    Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatments for bullous pemphigoid.
    Garrido PM; QueiróS CS; Travassos AR; Borges-Costa J; Filipe P
    J Dermatolog Treat; 2022 Mar; 33(2):649-661. PubMed ID: 32536232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
    Messingham KN; Pietras TA; Fairley JA
    G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
    Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
    Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
    Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
    Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
    Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
    Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
    Ujiie H
    J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
    Skaria M; Jaunin F; Hunziker T; Riou S; Schumann H; Bruckner-Tuderman L; Hertl M; Bernard P; Saurat JH; Favre B; Borradori L
    J Invest Dermatol; 2000 May; 114(5):998-1004. PubMed ID: 10771483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin.
    Sitaru C; Schmidt E; Petermann S; Munteanu LS; Bröcker EB; Zillikens D
    J Invest Dermatol; 2002 Apr; 118(4):664-71. PubMed ID: 11918714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
    de Graauw E; Sitaru C; Horn M; Borradori L; Yousefi S; Simon HU; Simon D
    Allergy; 2017 Jul; 72(7):1105-1113. PubMed ID: 28135772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.
    Chen HC; Wang CW; Toh WH; Lee HE; Chung WH; Chen CB
    Clin Rev Allergy Immunol; 2023 Dec; 65(3):331-353. PubMed ID: 37897588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases.
    Moriuchi R; Nishie W; Ujiie H; Natsuga K; Shimizu H
    J Dermatol Sci; 2015 Apr; 78(1):21-5. PubMed ID: 25724363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of bullous pemphigoid].
    Göbel M; Eming R
    Hautarzt; 2019 Apr; 70(4):236-242. PubMed ID: 30874841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models.
    Sasaoka T; Ujiie H; Nishie W; Iwata H; Ishikawa M; Higashino H; Natsuga K; Shinkuma S; Shimizu H
    J Invest Dermatol; 2018 Jun; 138(6):1260-1267. PubMed ID: 29391250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
    Karakioulaki M; Eyerich K; Patsatsi A
    Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
    Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.